| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Aldeyra Therapeutics, Inc. (ALDX) has 2 insiders with recent SEC Form 4 filings, including 9 buys and 2 sells. ALDX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 221.8K | $434.7K | - | |
| Other | 7.5K | $14.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 6, 2019 | Clark David J | Chief Medical Officer | Buy | 5,000 | $5.06 | $25,311.00 | +38.8% | |
| Sep 5, 2019 | Reed Joshua | Chief Financial Officer | Buy | 3,200 | $4.71 | $15,072.00 | +9.8% | |
| Sep 5, 2019 | McMullin David | Chief Commerical Officer | Buy | 4,329 | $4.68 | $20,259.72 | +238.0% | |
| Mar 26, 2019 | Treu Jesse I | Director | Sell | 96,743 | $10.01 | $968,397.43 | -4.9% | |
| Sep 19, 2017 | Perceptive Advisors LLC51 | 10% Owner | Buy | 200,000 | $7.25 | $1,450,000.00 | +6.9% | |
| Jun 30, 2017 | Perceptive Advisors LLC51 | 10% Owner | Buy | 296,007 | $4.60 | $1,361,632.20 | +11.4% | |
| Feb 17, 2017 | Brady Todd C | President And CEO | Buy | 22,223 | $4.50 | $100,003.50 | +52.7% | |
| Feb 17, 2017 | Tulipano Stephen J | Chief Financial Officer | Buy | 3,333 | $4.50 | $14,998.50 | New | |
| Feb 17, 2017 | Joyce Martin Joseph | Director | Buy | 4,444 | $4.50 | $19,998.00 | +32.9% | |
| Feb 17, 2017 | Bronstein Ben | Director | Buy | 4,444 | $4.50 | $19,998.00 | +35.6% |